메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
고려대학교 법학연구원 고려법학 고려법학 제56호
발행연도
2010.1
수록면
95 - 136 (42page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Deciding liability for defective drug designs have to consider drug designs are different from other products. Because drugs have characteristics that are chemical compounds designed to interact with the chemical and physiological processes of the human individuals. Drugs are most cost-effective input in supplying the demand for health. Comment (k) to the Restatement (Second) of Torts §402 A creates an exception to strict liability for "unavoidably unsafe" products. The vast majority of cases that apply comment (k) have involved drugs,vaccines, blood, and medical devices. The Restatement (Third) of Torts uses foresight in all design, it does not require a section exempting drug and medical device manufacturers from strict liability. However it has a special provision(§6), a prescription drug is not reasonably safe due to defective design if the foreseeable risks of harm posed by the drug or medical device are sufficiently great in relation to its foreseeable therapeutic benefits that reasonable health-care providers,knowing of such foreseeable risks and therapeutic benefits, would not prescribe the drug or medical device for any class of patients. A Product is defective in design when the foreseeable risks of harm posed by the product could have been reduced or avoided by the adoption of a reasonable alternative design and the omission of the alternative design renders the product not safe. Therefore courts that decide liability for defective drug designs,they have to apply risk-utility balance test on a case-by-case basis. I dissent that all drug are exempt from strict liability for design defect, even though alternative drugs can provide the same or even better, therapy, with less risk to life or health. I dissent categorical exemption like prescription drugs by health-care providers. A broad range of factors may be considered in determining whether an alternative design is reasonable and whether its omission renders a product not resonably safe(§2.2). KFDA(Korea Food & Drug Administration) safety procedures and its approval do not justify abdication of judical responsibility.

목차

등록된 정보가 없습니다.

참고문헌 (25)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0